AML clinical trials: early stage vs. relapse/refractory patients
The CLL2-BAG trial: can CLL patients safely cease treatment after remission?
Ibrutinib combination regimens for CLL from ASH 2017
How can MRD and disease be assessed in routine practice?
How is the landscape of Hodgkin lymphoma therapy changing?